Celgene Corporation et al v. Teva Pharmaceuticals, Inc.
| Celgene Corporation, Celgene International Sarl and Bristol-Myers Squibb Company |
| Teva Pharmaceuticals, Inc. |
| 1:2023cv01008 |
| September 13, 2023 |
| US District Court for the District of Delaware |
| Richard G Andrews |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on October 26, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 13 STIPULATION to Extend Time - filed by Teva Pharmaceuticals, Inc.. (Keller, Karen) Modified on 10/26/2023 (nms). |
SO ORDERED, re #13 STIPULATION to Extend Time (*Reset Answer Deadlines: Teva Pharmaceuticals, Inc. answer due 11/20/2023). Signed by Judge Richard G. Andrews on 10/26/2023. (nms)
|
| Pro Hac Vice Attorney Ivan M. Poullaos,George C. Lombardi, and Elise M. LeCrone for Teva Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mkr) |
| Filing 12 MOTION for Pro Hac Vice Appearance of Attorney George Lombardi, Ivan Poullaos and Elise M. LeCrone - filed by Teva Pharmaceuticals, Inc.. (Keller, Karen) |
|
SO ORDERED, re #12 MOTION for Pro Hac Vice Appearance of Attorney George Lombardi, Ivan Poullaos and Elise M. LeCrone, filed by Teva Pharmaceuticals, Inc.. Signed by Judge Richard G. Andrews on 10/23/2023. (nms)
|
| Pro Hac Vice Attorney David Mlaver for Celgene Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:23-cv-01008-RGA, 1:23-cv-01019-RGA(mpb) |
| Pro Hac Vice Attorney Heather M. Petruzzi, Amy K. Wigmore, Gerard A. Salvatore, Nora Q.E. Passamaneck, Andrew J. Danford, and Li-tsung A. Chen for Celgene Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:23-cv-01008-RGA, 1:23-cv-01019-RGA(mpb) |
| Filing 11 STIPULATION to Extend Time - filed by Teva Pharmaceuticals, Inc.. (Keller, Karen) Modified on 9/26/2023 (nms). |
|
SO ORDERED, re #11 STIPULATION to Extend Time (*Reset Answer Deadlines: Teva Pharmaceuticals, Inc. answer due 11/6/2023). Signed by Judge Richard G. Andrews on 9/26/2023. (nms)
|
| Filing 10 Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd. for Teva Pharmaceuticals, Inc. filed by Teva Pharmaceuticals, Inc.. (Keller, Karen) |
| DEFICIENCY NOTICE issued by the Court to Defendant: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (nms) |
|
SO ORDERED, re #8 MOTION for Pro Hac Vice Appearance of Attorney Amy K. Wigmore, Heather M. Petruzzi, Andrew J. Danford, Nora Q.E. Passamaneck, David Mlaver, Gerard A. Salvatore, and Li-tsung Alyssa Chen, filed by Celgene Corporation, Celgene International Sarl, Bristol-Myers Squibb Company. Signed by Judge Richard G. Andrews on 9/20/2023. (nms)
|
| Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Filing 9 NOTICE of Appearance by Karen Elizabeth Keller on behalf of Teva Pharmaceuticals, Inc. (Keller, Karen) |
| Filing 8 MOTION for Pro Hac Vice Appearance of Attorney Amy K. Wigmore, Heather M. Petruzzi, Andrew J. Danford, Nora Q.E. Passamaneck, David Mlaver, Gerard A. Salvatore, and Li-tsung Alyssa Chen - filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (Farnan, Brian) |
| Filing 7 SUMMONS Returned Executed by Celgene Corporation, Bristol-Myers Squibb Company, Celgene International Sarl.Teva Pharmaceuticals, Inc. served on 9/14/2023, answer due 10/5/2023. (Farnan, Michael) |
| Filing 6 Summons Issued as to Teva Pharmaceuticals, Inc. on 9/13/2023. (mpb) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bristol-Myers Squibb Company for Celgene Corporation; Corporate Parent Celgene Corporation for Celgene International Sarl filed by Bristol-Myers Squibb Company, Celgene Corporation, Celgene International Sarl. (mpb) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,846,628 B2 ;US 11,571,436 B2. (mpb) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 8/11/2023. Date of Expiration of Patent: 6/3/2030 & 5/14/2029.Thirty Month Stay Deadline: 2/11/2026. (mpb) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) |
| Filing 1 COMPLAINT filed against Teva Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4223159.) - filed by Celgene Corporation, Bristol-Myers Squibb Company, Celgene International Sarl. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Civil Cover Sheet)(mpb) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
